Compare SHO & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHO | COAG |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2004 | 2026 |
| Metric | SHO | COAG |
|---|---|---|
| Price | $11.09 | $38.25 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $9.79 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 366.5K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $1,115,167,000.00 | N/A |
| Revenue This Year | $3.95 | N/A |
| Revenue Next Year | $2.30 | N/A |
| P/E Ratio | $50.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.69 | $27.47 |
| 52 Week High | $12.07 | $55.42 |
| Indicator | SHO | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 35.66 |
| Support Level | $10.99 | $29.54 |
| Resistance Level | $11.46 | $38.87 |
| Average True Range (ATR) | 0.18 | 3.04 |
| MACD | 0.03 | -0.48 |
| Stochastic Oscillator | 89.11 | 13.71 |
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in California which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its Hotel Ownership Segment.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.